The Combined Dexamethasone/CRH Test (DEX/CRH Test) and Prediction of Acute Treatment Response in Major Depression

被引:66
|
作者
Schuele, Cornelius [1 ]
Baghai, Thomas C. [1 ]
Eser, Daniela [1 ]
Haefner, Sibylle [1 ]
Born, Christoph [1 ]
Herrmann, Sascha [1 ]
Rupprecht, Rainer [1 ]
机构
[1] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
来源
PLOS ONE | 2009年 / 4卷 / 01期
关键词
CORTICOTROPIN-RELEASING HORMONE; MESSENGER-RNA EXPRESSION; FREE CORTISOL EXCRETION; DEX-CRH TEST; SUPPRESSION TEST; NEUROENDOCRINE REGULATION; PARAVENTRICULAR NUCLEUS; LABORATORY TEST; AXIS ACTIVITY; NORMALIZATION;
D O I
10.1371/journal.pone.0004324
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: In this study the predictive value of the combined dexamethasone/CRH test (DEX/CRH test) for acute antidepressant response was investigated. Methodology/Principal Findings: In 114 depressed inpatients suffering from unipolar or bipolar depression (sample 1) the DEX/CRH test was performed at admission and shortly before discharge. During their stay in the hospital patients received different antidepressant treatment regimens. At admission, the rate of nonsuppression (basal cortisol levels > 75.3 nmol/l) was 24.6% and was not related to the later therapeutic response. Moreover, 45 out of 114 (39.5%) patients showed an enhancement of HPA axis function at discharge in spite of clinical improvement. In a second sample, 40 depressed patients were treated either with reboxetine or mirtazapine for 5 weeks. The DEX/CRH test was performed before, after 1 week, and after 5 weeks of pharmacotherapy. Attenuation of HPA axis activity after 1 week was associated with a more pronounced alleviation of depressive symptoms after 5-week mirtazapine treatment, whereas downregulation of HPA system activity after 5 weeks was related to clinical response to reboxetine. However, early improvement of HPA axis dysregulation was not necessarily followed by a beneficial treatment outcome. Conclusions/Significance: Taken together, performance of a single DEX/CRH test does not predict the therapeutic response. The best predictor for response seems to be an early attenuation of HPA axis activity within 1 or 2 weeks. However, early improvement of HPA system dysfunction is not a sufficient condition for a favourable response. Since a substantial part of depressive patients display a persistence of HPA axis hyperactivity at discharge, downregulation of HPA system function is not a necessary condition for acute clinical improvement either. Our data underline the importance of HPA axis dysregulation for treatment outcome in major depression, although restoration of HPA system dysfunction seems to be neither a necessary nor a sufficient determinant for acute treatment response.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Combined DEX/CRH test among Japanese patients with major depression
    Kunugi, H
    Urushibara, T
    Nanko, S
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2004, 38 (02) : 123 - 128
  • [2] The combined dexamethasone/CRH test: Biomarker in depression
    Ising, M.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S64 - S64
  • [3] The DEX/CRH test for major depression: A potentially useful diagnostic test
    Mokhtari, Mohammadreza
    Arfken, Cynthia
    Boutros, Nash
    [J]. PSYCHIATRY RESEARCH, 2013, 208 (02) : 131 - 139
  • [4] Lithium Augmentation Increases the ACTH and Cortisol Response in the Combined DEX/CRH Test in Unipolar Major Depression
    Tom Bschor
    Mazda Adli
    Christopher Baethge
    Uta Eichmann
    Marcus Ising
    Manfred Uhr
    Sieglinde Modell
    Heike Künzel
    Bruno Müller-Oerlinghausen
    Michael Bauer
    [J]. Neuropsychopharmacology, 2002, 27 : 470 - 478
  • [5] Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression
    Bschor, T
    Adli, M
    Baethge, C
    Eichmann, U
    Ising, M
    Uhr, M
    Modell, S
    Künzel, H
    Müller-Oerlinghausen, B
    Bauer, M
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 27 (03) : 470 - 478
  • [6] The combined DEX-CRH test in treatment course and long-term outcome of major depression
    Hatzinger, M
    Hemmeter, UM
    Baumann, K
    Brand, S
    Holsboer-Trachsler, E
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2002, 36 (05) : 287 - 297
  • [7] Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression
    Baghai, TC
    Schüle, C
    Zwanzger, P
    Minov, C
    Holme, C
    Padberg, F
    Bidlingmaier, M
    Strasburger, CJ
    Rupprecht, R
    [J]. PSYCHONEUROENDOCRINOLOGY, 2002, 27 (03) : 385 - 399
  • [8] Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls
    Carpenter, Linda L.
    Ross, Nicole S.
    Tyrka, Audrey R.
    Anderson, George M.
    Kelly, Megan
    Price, Lawrence H.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2009, 34 (08) : 1208 - 1213
  • [9] Impact of dexamethasone metabolism on dex/CRH-test
    Lister, Eleanor Ann
    Sigalas, Paul
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2011, 45 (11) : 1542 - 1542
  • [10] The influence of psychiatric comorbidity on the dexamethasone/CRH test in major depression
    Veen, Gerthe
    DeRijk, Roel H.
    Giltay, Erik J.
    van Vliet, Irene M.
    van Pelt, Johannes
    Zitman, Frans G.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (06) : 409 - 415